HOME > News > Press Releases > 2025.1.10 Totipro® Wins National Innovation Awards — Redefining the Future of Postbiotics

News

2025.1.10 Totipro® Wins National Innovation Awards — Redefining the Future of Postbiotics

Share to
Glac Biotech’s pioneering postbiotic ingredient, Totipro®, continues to shine on both domestic and international stages. First honored with the National Innovation Award in 2019, Totipro® reached another milestone in 2024, earning the National Innovation Excellence Award — a testament to its enduring impact and innovation in the health and nutrition industry.

The Breakthrough: HeaLAC® Heat-Lock Technology
At the heart of Totipro® lies Glac’s patented HeaLAC® heat-lock process, a breakthrough that preserves the bioactive metabolites of probiotics after fermentation. This ensures Totipro® retains nutrient-rich postbiotic compounds while delivering superior stability.
Unlike traditional probiotics, Totipro® is heat-resistant, stable, and versatile, making it suitable for capsules, sachets, protein powders, gummies, and beverages. For food and supplement manufacturers, this flexibility opens the door to next-generation formulations that meet evolving consumer needs.

Tailored Solutions for Gut Health
Recognizing that different sections of the digestive tract face unique challenges, Glac developed two targeted Totipro® solutions:
  • Upper GI tract: Supports oral-to-stomach microbiome balance.
  • Lower GI tract: Strengthens intestinal mucosa, boosts beneficial bacteria, and optimizes gut ecology.
This dual approach positions Totipro® as a comprehensive solution for digestive wellness.

Global Recognition and Patents
Totipro® has already secured patents in Taiwan, the U.S., Japan, and the EU, validating its scientific and commercial value.
Its proven benefits — from oral and gastric health to microbiome support and bowel regularity — have also earned international acclaim. In 2023 and 2024, Totipro® was awarded the NutraIngredients Microbiome Modulation Award two years in a row, cementing its status as a global leader in postbiotics.

Looking Ahead: Clinical Research and Market Positioning
Glac Biotech isn’t slowing down. In 2025, the company will partner with leading teaching hospitals to expand clinical trials on Totipro®, strengthening its scientific foundation and clarifying its position in the global health market.
For Glac, the journey of Totipro® is more than just innovation — it’s about transforming scientific breakthroughs into real-world health solutions.
 

 

Media Coverage (Extended Reading)

 

Previous Back to list Next
Back
TOP